ERBB2 G309A

CI-VAR-00001701Explore in graph →NP_004439.2:p.Gly309AlaNM_004448.3:c.926G>CClinVar 376205 CIViC 38 rs1057519787

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm2
ERBB2 G309A	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	submitted	EID11490 Cell proliferation analysis of NIH 3T3 cells harboring the G309A variation exhibit an increase of colony formation in soft agar compared with a wild-type ERBB2 and cells with ERBB2 D845A kinase-inacti… (full text at CIViC) PMID 22908275 · Greulich et al., 2012 · Open in CIViC	civic
ERBB2 G309A	Neratinib	Predictive	D	Supports Sensitivity Response	5	accepted	EID282 In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC	civic
Unmapped disease2

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.